SLC5A2 and heart failure: A meta-analysis of 11 randomized trials evaluating SGLT2 inhibitors demonstrated a significant reduction in major adverse cardiovascular events (MACE), with the observed decrease in cardiovascular mortality primarily driven by reductions in heart failure-related deaths and sudden cardiac death.